- Raw materials
- Antibacterials
- Metampicillin
Metampicillin API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Metampicillin | CAS No: 6489-97-0 | GMP-certified suppliers
A medication that delivers systemic antibacterial activity through prodrug conversion, targeting a broad spectrum of infections with efficacy primarily against Gram-positive and some Gram-negative bacteria.
Therapeutic categories
Product Snapshot
- Metampicillin is an oral small molecule antibiotic formulation
- It is primarily investigated for bacterial infection treatment
- The compound is currently in experimental stages and not approved by major regulatory agencies
Clinical Overview
Pharmacologically, metampicillin functions as a prodrug; upon administration, it undergoes rapid hydrolysis in aqueous and acidic environments, such as the gastric milieu, to release the active agent ampicillin. This hydrolytic conversion facilitates systemic availability of ampicillin, a beta-lactam antibiotic with a broad spectrum of bactericidal activity primarily against Gram-positive and some Gram-negative organisms.
Mechanistic details specific to metampicillin are not extensively characterized, but its therapeutic efficacy relies on the activity of its metabolite, ampicillin. Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, thereby disrupting peptidoglycan cross-linking essential for cell wall integrity.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for metampicillin are closely linked to its biotransformation to ampicillin. Hydrolysis in the stomach leads to absorption of ampicillin, which is distributed systemically, minimally metabolized, and primarily excreted unchanged by the kidneys.
Safety and toxicity profiles of metampicillin are expected to parallel those of ampicillin, including risks of hypersensitivity reactions characteristic of beta-lactam antibiotics, possible gastrointestinal disturbances, and rare occurrences of hematologic or hepatic effects. However, comprehensive clinical safety data specific to metampicillin are limited, as its use remains experimental.
Metampicillin has no approved clinical indications or extensively documented therapeutic applications and remains largely of investigational interest. Notable marketed products are not established.
For pharmaceutical development and sourcing, it is essential to procure metampicillin API with rigorous quality control to ensure purity and consistent hydrolytic conversion to ampicillin. Stability considerations under acidic and aqueous conditions necessitate controlled manufacturing and storage environments. Suppliers should provide comprehensive analytical data including impurity profiling to support regulatory compliance.
Identification & chemistry
| Generic name | Metampicillin |
|---|---|
| Molecule type | Small molecule |
| CAS | 6489-97-0 |
| UNII | G0H6U7VSTK |
| DrugBank ID | DB13836 |
Formulation & handling
- Metampicillin is a small molecule beta-lactam antibiotic suitable for oral administration due to its penicillin core structure.
- It exhibits low lipophilicity and limited water solubility, which may require formulation strategies to enhance bioavailability.
- Stability considerations include protection from moisture and acidic environments to preserve the beta-lactam ring integrity.
Regulatory status
Metampicillin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
